Sector News

Carolyn Logan to Retire as Chief Executive Officer of Salix Pharmaceuticals

January 6, 2015
Life sciences
Salix Pharmaceuticals, Ltd. today announced that Carolyn Logan has informed the Board of her decision to retire as President and Chief Executive Officer, and as a director, of the Company, effective January 30, 2015. Ms. Logan will remain a consultant to the Company.
 
“What Carolyn has accomplished in the 12-1/2 years she has led our Company is remarkable,” said Tom D’Alonzo, Chairman of Salix’s Board of Directors. “The Board extends Carolyn its deepest gratitude for taking Salix from an early-stage commercial company with a market capitalization of approximately $200 million, one product and less than $25 million in annual revenues, to a leading gastroenterology-focused specialty pharmaceutical company with a multi-billion dollar market capitalization, more than 20 products and over $1.0 billion in annual revenues. We will miss Carolyn’s leadership and enthusiasm, and wish her the best of luck as she enters this next exciting chapter.”
 
Ms. Logan said, “It has been an honor and a privilege to have worked with so many talented people at Salix for more than a decade. I am extremely proud of what this extraordinary group has accomplished for our shareholders, physicians and patients.”
 
Effective January 30, 2015, Mr. D’Alonzo, who has significant experience as a chief executive in the pharmaceutical industry, will be appointed Acting Chief Executive Officer, and William Bertrand, Jr., the Company’s Senior Vice President and General Counsel, will be appointed Acting Chief Operating Officer, pending the Company’s hiring of a permanent Chief Executive Officer.
 
Salix intends to retain a nationally recognized executive search firm to assist the Company in identifying a highly qualified, experienced pharmaceutical executive to lead the Company on a going-forward basis.
 
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix’s strategy is to in-license or acquire late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and commercialize them through Salix’s 500-member specialty sales force.
 
Source: Salix 

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend